Compare ACADIA Pharmaceuticals Inc. (ACAD) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs UnitedHealth Group Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while UnitedHealth Group Inc trades at $425.14 (market cap $388.86B). The key difference: UnitedHealth Group Inc is far larger — about 86.6× ACADIA Pharmaceuticals Inc.'s market cap, and UnitedHealth Group Inc pays a 2.17% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | UNH | |
|---|---|---|
Market Cap | $4.49B | $388.86B |
Sector | Health | Health |
52-Week High | $28.06 | $428.19 |
52-Week Low | $20.06 | $237.77 |
Enterprise Value | $3.69B | $435.55B |
Dividend Yield | — | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
UnitedHealth Group (UNH) trades at $417.99, down 1.73% today, but maintains a bullish technical signal with strong moving averages and support near $414. Revenue grew to $447.57B in 2025, though net income margin compressed to 2.68%. Recent news highlights strategic moves to reduce pediatric prior authorizations and ongoing shareholder returns via dividends and buybacks.
Outlook remains positive with analyst consensus at Buy (82.69%) and a $419.47 price target, though regulatory risks from lawsuits and margin pressures pose challenges. The stock's valuation at a P/E of 31.48 appears rich relative to historical norms, requiring sustained earnings growth to justify further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
